These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25065545)

  • 1. The quality of reporting of phase II and III trials for new antipsychotics: a systematic review.
    Patel MX; Collins S; Hellier J; Bhatia G; Murray RM
    Psychol Med; 2015 Feb; 45(3):467-79. PubMed ID: 25065545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.
    Naber D; Lambert M
    CNS Drugs; 2009 Aug; 23(8):649-59. PubMed ID: 19594194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
    De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
    CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
    Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
    CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.
    Kruse G; Wong BJ; Duh MS; Lefebvre P; Lafeuille MH; Fastenau JM
    Pharmacoeconomics; 2015 Oct; 33(10):1049-67. PubMed ID: 25963579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.
    Achilla E; McCrone P
    Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
    Leucht S; Cipriani A; Spineli L; Mavridis D; Orey D; Richter F; Samara M; Barbui C; Engel RR; Geddes JR; Kissling W; Stapf MP; Lässig B; Salanti G; Davis JM
    Lancet; 2013 Sep; 382(9896):951-62. PubMed ID: 23810019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What do large scale studies of medication in schizophrenia add to our management strategies?
    Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
    Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.
    Foussias G; Remington G
    Can J Psychiatry; 2010 Mar; 55(3):117-25. PubMed ID: 20370961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?
    Attard A; Taylor DM
    CNS Drugs; 2012 Jun; 26(6):491-508. PubMed ID: 22668246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
    Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study.
    Schulz C; Timm J; Cordes J; Gründer G; Mühlbauer B; Rüther E; Heinze M
    Clin Trials; 2016 Jun; 13(3):251-9. PubMed ID: 27016729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review.
    Druyts E; Zoratti MJ; Toor K; Wu P; Kanji S; Rabheru K; Mills EJ; Thorlund K
    BMC Pediatr; 2016 Nov; 16(1):181. PubMed ID: 27825323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotics and metabolics in the post-CATIE era.
    Meyer JM
    Curr Top Behav Neurosci; 2010; 4():23-42. PubMed ID: 21312396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benzodiazepines for schizophrenia.
    Volz A; Khorsand V; Gillies D; Leucht S
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006391. PubMed ID: 17253592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.
    De Hert M; Sermon J; Geerts P; Vansteelandt K; Peuskens J; Detraux J
    CNS Drugs; 2015 Aug; 29(8):637-58. PubMed ID: 26293744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.